Project Grant R41NS125874

Award Date 9/20/22
Completion Date 8/31/24
Dollars Obligated $680K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40513, USA
Similar Awards
This Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $1,727,088 to Albert Einstein College of Medicine to investigate restoring ependymal integrity as a means to reduce post-hemorrhagic hydrocephalus in preterm infants. The project aims to evaluate the impact of intraventricular hemorrhage (IVH) on the proliferation and maturation of...
This Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop a novel, less invasive tool to ablate the choroid plexus for the treatment of neonatal hydrocephalus. The $789,088 award to Children's Hospital Medical Center, with a sub-award to the University of Cincinnati, will fund the evaluation of this tool in human choroid...
This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund a comprehensive genomic, clinical, and neuroimaging study of congenital hydrocephalus (CH). The $666,728 award to The Washington University in St. Louis aims to establish the largest and most diverse cohort of CH patients to date, with a focus on underrepresented...
This $307,202 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by Wayne State University to optimize shunt catheters for the treatment of hydrocephalus. The award, with an initial term from January 15, 2024 to January 14, 2026, will fund experimental, computational, and analytical studies focused on biomechanics, human injury tolerance, anthropomorphic test device evaluation, and computational modeling...
The University of Alabama at Birmingham (UAB) has been awarded a $392,855 Project Grant (R21NS135321) from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to conduct research on the underlying genetic and cellular mechanisms of congenital hydrocephalus. The project aims to 1) comprehensively characterize germline and somatic genetic variations in hydrocephalus patients using...
This Project Grant award of $298,772.00 from the National Institute on Minority Health and Health Disparities (CFDA 93.307 - Minority Health and Health Disparities Research) supports the development and evaluation of FlowSense, a flexible, wearable device that allows for a non-invasive, radiation-free assessment of cerebrospinal fluid (CSF) flow for pediatric hydrocephalus patients in Puerto Rico. The 6-month project, awarded to Rhaeos, Inc. on Apr 12, 2025, aims to: 1) Evaluate the utility of...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Neuroscope Inc. in the amount of $1,193,370 aims to develop a computational toolset for mapping and quantifying perivascular space (PVS) morphology from MRI. The goal is to create a non-invasive, automated method to assess PVS, which is an important diagnostic feature for Alzheimer's disease and vascular dementia. The funded work will build the IT infrastructure to commercialize Neuroscope's PVS...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $1,386,770 to VON Vascular, Inc. to develop a novel aspiration pump for neurointerventional procedures. The goal is to create an improved aspiration pump that can increase first-pass revascularization rates and reduce medical waste, compared to existing market-leading devices....
This $638,804 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Pennsylvania State University's Milton S. Hershey Medical Center aims to integrate cerebrospinal fluid (CSF) proteogenomic analyses to improve diagnosis and management of diffuse gliomas, the most common primary malignant adult brain tumors. The key objectives are to: 1) validate preliminary findings on CSF-based proteomic signatures that can differentiate diffuse...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the Department of Health and Human Services, awarded a $179,000 Project Grant under CFDA 93.286 "Discovery and Applied Research for Technological Innovations to Improve Human Health" to Brigham & Women's Hospital Inc. to develop image processing algorithms for improving the visualization and interpretation of digital subtraction angiography (DSA) imaging used for cerebrovascular surgical planning....

IMPROVED DIAGNOSIS OF SHUNT MALFUNCTION WITH AUTOMATIC QUANTIFICATION OF VENTRICULAR SPACE - ABSTRACT HYDROCEPHALUS IS THE BUILDUP OF CEREBROSPINAL FLUID (CSF) IN THE CAVITIES (VENTRICLES) DEEP WITHIN THE BRAIN. THE MOST COMMON TREATMENT FOR HYDROCEPHALUS IS CSF DIVERSION VIA VENTRICULOPERITONEAL (VP) SHUNTING. OVER 30,000 VP SHUNTS ARE PLACED PER YEAR IN THE UNITED STATES BY SOME ESTIMATES. DESPITE HOW COMMONLY THIS SURGERY IS PERFORMED, THE COMPLICATION RATE HAS BEEN ESTIMATED AT ALMOST 24%, WITH ONE REPORT CITING A 22% RATE OF REVISION. NEARLY 50% OF PATIENTS ADMITTED WITH SHUNT RELATED ISSUES REQUIRE A STAY OF FIVE OR MORE DAYS. GIVEN THE RATE OF SURGICAL SITE INFECTIONS AND COMPLICATIONS ASSOCIATED WITH SHUNT EXPLORATIONS AND REVISIONS, ACCURATE DIAGNOSIS OF A SHUNT MALFUNCTION REMAINS A CRITICAL, IF ELUSIVE, GOAL FOR MANY NEUROSURGEONS. ONE OF THE DIFFICULTIES IN ESTABLISHING A DIAGNOSIS BASED ON IMAGING ALONE IS THE LACK OF STANDARDIZED ROBUST METHODS OF MEASURING VENTRICULAR SIZE. RECENTLY VOLUMETRIC ANALYSES HAVE BEEN STUDIED AS A METHOD FOR MEASURING VENTRICULAR SIZE, AS COMPARED TO THE EVANS' INDEX OR FRONTAL-OCCIPITAL HORN RATIOS AND HAVE BEEN SUGGESTED IS MORE ACCURATE AND A BETTER TOOL FOR MEASURING RESPONSE OF VENTRICULAR SIZE TO SHUNTING. HOWEVER, THE ASSOCIATED HUMAN EFFORTS AND INTER- AND INTRA-OBSERVER VARIABILITY IN SEGMENTING THE VENTRICLES PROHIBITS ITS WIDE CLINICAL ADOPTION. THE OTHER DIFFICULTY WITH ESTABLISHING A DIAGNOSIS OF VENTRICULOMEGALY OR HYDROCEPHALUS, INVOLVES A LACK OF A STANDARDIZED, NORMATIVE DATASET WITH A RANGE OF WHAT IS CONSIDERED "NORMAL" FOR VARIOUS AGE RANGES AS THE VENTRICLE SIZE INCREASES WITH AGE. CURRENT LITERATURE LACKS A ROBUST NORMATIVE DATASET OF VENTRICULAR SIZE BY AGE AND GENDER AND ONLY RECENTLY HAS SUCH A DATASET BEEN PRODUCED FOR THE PEDIATRIC AGE RANGE. ESTABLISHMENT OF NORMATIVE VALUES FOR VENTRICULAR VOLUME AND MORPHOLOGY ACROSS ALL AGE POPULATION IS SORELY NEEDED AND WILL ALLOW FOR THE INVESTIGATION OF A VARIETY OF TOPICS RELATED TO HYDROCEPHALUS AND ULTIMATELY ASSISTING IN THE DETECTION AND TRIAGE OF HYDROCEPHALUS AND VP SHUNT RELATED COMPLICATIONS OR MALFUNCTIONS. IN RECENT YEARS, THE RAPID DEVELOPMENT OF DEEP LEARNING (DL) MODELS HAS LED TO GREAT IMPACT ON MANY AREAS OF MEDICINE, ESPECIALLY FOR AUTOMATIC IMAGE ANALYSIS TASKS INCLUDING SEGMENTATION. TAKING ADVANTAGE OF DL MODELS, TWO AIMS ARE PROPOSED IN THIS PROJECT: 1) DEVELOP AND VALIDATE A ROBUST DL MODEL FOR VENTRICLE SEGMENTATION INCLUDING MULTI-MODALITY SUPPORT AND AUTOMATIC FAILURE DETECTION AND BUILD A NORMATIVE DATABASE; 2) DEVELOP A SOFTWARE PROTOTYPE THAT INCORPORATES THE DL MODEL AND NORMATIVE VALUES AND FITS THE CLINICAL WORKFLOW FOR IMAGE-BASED DIAGNOSIS OF SHUNT MALFUNCTION. ULTIMATELY, A UNIQUE SOFTWARE PRODUCT WILL BE DEVELOPED AND COMMERCIALIZED TO IMPROVE THE DIAGNOSIS OF SHUNT MALFUNCTION AND HYDROCEPHALUS AND BENEFIT THE PATIENTS WITH BETTER SURGICAL OUTCOME AND REDUCED COST.

Posted 9/19/22, 12:00 AM